Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

254.76
-6.3100-2.42%
Pre-market: 257.552.79+1.10%08:43 EDT
Volume:8.58M
Turnover:2.19B
Market Cap:450.26B
PE:125.49
High:260.92
Open:259.92
Low:253.60
Close:261.07
52wk High:261.64
52wk Low:184.63
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.51
T/O Rate:0.49%
Dividend:6.74
Dividend Rate:2.65%
EPS(TTM):2.03
EPS(LYR):2.36
ROE:6225.00%
ROA:10.03%
PB:-67.65
PE(LYR):107.95

Loading ...

AbbVie Updates Q2, Full Year Guidance

MT Newswires Live
·
15 hours ago

Therapeuticsmd Inc. Stock Slides 6.6%, Underperforms Market

Dow Jones
·
16 hours ago

Abbvie Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
16 hours ago

AbbVie says Q2 EPS to include unfavorable impact of 17c

TIPRANKS
·
16 hours ago

AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77

TIPRANKS
·
16 hours ago

AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28

TIPRANKS
·
16 hours ago

Abbvie Cuts Q2 Adjusted EPS View to USD 3.57-3.61 on USD 291 Million Acquired Ipr&d, Milestones Charge

Reuters
·
16 hours ago

Abbvie - Q2 2026 Includes $291 Mln Bought Ipr&d Expense, Impacting Gaap and Adj Diluted EPS by $0.17 - SEC Filing

THOMSON REUTERS
·
16 hours ago

Abbvie Says Tepkinly in Combination with Lenalidomide and Rituximab Approved by European Commission

Reuters
·
18 hours ago

AbbVie says Tepkinly combo approved by EC for lymphoma treatment

TIPRANKS
·
18 hours ago

Abbvie Says EU Clears Tepkinly Combo for Relapsed or Refractory Follicular Lymphoma

Reuters
·
18 hours ago

Abbvie Announces Tepkinly® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

THOMSON REUTERS
·
18 hours ago

AbbVie price target raised to $300 from $275 at HSBC

TIPRANKS
·
Yesterday

Abbvie is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Yesterday

Cantor Fitzgerald Adjusts AbbVie Price Target to $265 From $240

MT Newswires Live
·
Yesterday

Leerink Starts Avalo at "outperform" on Skin Disease Drug Potential

Reuters
·
Yesterday

U.S. Research Roundup-east West Bancorp, First Citizens Bancshares, UMB Financial

Reuters
·
Yesterday

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide

Reuters
·
Yesterday

Abbvie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 03

Sector Update: Healthcare Stocks Gain Thursday Afternoon

MT Newswires Live
·
Jul 03